Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Severe Acute Respiratory Syndrome 1Mastocytosis 1Hypersensitivity 1COVID-19 1

Interventions

Cyclophosphamide 143fludarabine phosphate 130Busulfan 109Tacrolimus 94fludarabine 93Mycophenolic Acid 90Whole-Body Irradiation 84Peripheral Blood Stem Cell Transplantation 81Imatinib Mesylate 69Antilymphocyte Serum 67Cyclosporine 66Azacitidine 64Cytarabine 63Methotrexate 60Melphalan 60Filgrastim 50Granulocyte Colony-Stimulating Factor 40Decitabine 40Thiotepa 38thymoglobulin 34Stem Cell Transplantation 34Dasatinib 34Radiotherapy 33nilotinib 31ruxolitinib 28Cord Blood Stem Cell Transplantation 28venetoclax 26Clofarabine 25Specimen Handling 24Methylprednisolone 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × BNT162 Vaccine × Myeloid × Clear all
NCT04761822 2025-08-12

SARS

National Institute of Allergy and Infectious Diseases (NIAID)

Phase 2 Completed
746 enrolled 28 charts
Myeloid

COVID-19, Hypersensitivity, Mastocytosis, Severe Acute Respiratory Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡